We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Amneal Pharmaceuticals Holding Co | NYSE:AMRX | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.87 | 0 | 01:00:00 |
*
|
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
|
1
|
Names of Reporting Persons
Chirag Patel
|
|||||
2
|
Check the Appropriate Box if a Member of a Group
(a) ☒ (b) ☐
|
|||||
3
|
SEC Use Only
|
|||||
4
|
Source of Funds (See Instructions)
OO
|
|||||
5
|
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
☐
|
|||||
6
|
Citizenship or Place of Organization
United States
|
|||||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
Sole Voting Power
21,300,504
|
||||
8
|
Shared Voting Power
0
|
|||||
9
|
Sole Dispositive Power
21,300,504
|
|||||
10
|
Shared Dispositive Power
0
|
|||||
11
|
Aggregate Amount Beneficially Owned by Each Reporting Person
21,300,504
|
|||||
12
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares
☐
|
|||||
13
|
Percent of Class Represented by Amount in Row (11)
14.3%(1)
|
|||||
14
|
Type of Reporting Person
IN
|
Reporting Person
|
|
Amount
beneficially owned(1) |
|
|
Percent
of class(1) |
|
|
Sole
power to vote or to direct the vote(1) |
|
|
Shared
power to vote or to direct the vote |
|
|
Sole power
to dispose or to direct the disposition(1) |
|
|
Shared
power to dispose or to direct the disposition |
|
||||||
Chirag Patel
|
|
|
21,300,504
|
|
|
|
14.3
|
%
|
|
|
21,300,504
|
|
|
|
0
|
|
|
|
21,300,504
|
|
|
|
0
|
|
(c)
|
During the past 60 days the Reporting Person has not effected any transactions in the Class A Common Stock.
|
(d)
|
None.
|
(e)
|
Not applicable.
|
Exhibit
Number
|
|
Description
|
1
|
|
Second Amended and Restated Stockholders Agreement, dated as of December 16, 2017, by and among the Amneal Group and Atlas Holdings, Inc. (incorporated by reference
to Annex B to the Issuer’s Registration Statement on Form S-4 filed on February 6, 2018).
|
2
|
Amendment No. 1 to Second Amended and Restated Stockholders Agreement, dated as of August 2, 2019, by and among the Amneal Group and Atlas Holdings, Inc.
(incorporated by reference to Exhibit 10.5 to the Issuer’s Quarterly Report on Form 10-Q filed on August 5, 2019).
|
|
3
|
|
Third Amended and Restated Limited Liability Company Agreement, adopted as of May 4, 2018 (incorporated by reference to Exhibit 10.5 to the Issuer’s Current Report on Form 8-K filed on May 7, 2018).
|
4
|
Securities Account Sole Control Agreement, dated as of June 10, 2019, by and among the Borrowers, Credit Suisse AG, Credit Suisse Securities (USA) LLC and Pershing
LLC.
|
|
5
|
Shares Issuer Agreement and Consent, dated as of June 10, 2019, by and among the Borrowers, Credit Suisse, Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals,
Inc.
|
|
/s/ Chirag Patel
|
||
Chirag Patel
|
|||
1 Year Amneal Pharmaceuticals Chart |
1 Month Amneal Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions